15N-Labeled Envafolimab
15N-Labeled Envafolimab is the 15N-labeled Envafolimab (HY-P99115). Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nM. Envafolimab has the potential for the research of solid tumors.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Species Reactivity
Human
In Vitro
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Gene ID
Accession
Target
B7-H1/PD-L1/CD274
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
SMILES
[15N-Labeled Envafolimab]
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Baculovirus-insect cell protein expression and purification
Baculovirus-insect cell expression uses recombinant baculovirus to deliver a target gene into insect cells, where late or very-late viral transcription drives recombinant protein production; the method was classically demonstrated by expression of human β-interferon in baculovirus-infected insect cells. The readout is target protein accumulation, assessed by activity, fluorescence if a fluorescent reporter is used, SDS-PAGE, Western blot, or purified protein yield. The system can express soluble, secreted, membrane-associated, and multiprotein targets, but expression outcome depends on the construct, baculovirus vector, insect cell line, multiplicity of infection, infection cell density, harvest time, and target-specific stability.
-
E. coli fusion-tag soluble protein purification
The purification of soluble recombinant proteins in Escherichia coli is achieved by fusing the target protein with a solubility-enhancing affinity tag (e. g. , His-tag, GST, MBP, Fh8, CSQ-tag, or thioredoxin) to improve expression yield, prevent aggregation, and enable efficient purification via affinity chromatography. The fusion protein is expressed under inducible promoters (e. g. , IPTG-induced T7 promoter), lysed from bacterial cells, and purified using resin-based affinity chromatography (e. g. , Ni-NTA for His-tag, amylose resin for MBP, chitin resin for intein tags, or HIC for Fh8). Tags can be removed post-purification using site-specific proteases (e. g. , TEV, enterokinase) or through intracellular cleavage systems. Solubility screening using multiple fusion partners (e. g. , Expresso® system) allows optimization of expression conditions for difficult-to-express proteins.
-
Inclusion-body expression, solubilization, refolding and purification
Inclusion-body recovery uses insoluble recombinant protein aggregates from E. coli as a starting material; the workflow is cell disruption, inclusion-body isolation/washing, denaturant or mild solubilization, refolding into soluble protein, and final chromatographic purification. The readouts are soluble protein recovery, purity by SDS-PAGE/chromatography, structural recovery by methods such as circular dichroism when used, and biological activity when an assay is available.
-
Protocol For Protein Expression And Purification
Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac
-
Mammalian transient protein expression and purification
Mammalian transient protein expression introduces plasmid DNA into HEK293 or CHO cells for short-term recombinant protein production, allowing secreted, glycosylated, Fc-tagged, His-tagged, or membrane proteins to be produced without stable clone generation.
Purity & Documentation
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)